Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001104659-24-100745
Filing Date
2024-09-17
Accepted
2024-09-17 19:17:50
Documents
1
Period of Report
2024-06-15

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2424255-4_4aseq1.html 4/A  
1 OWNERSHIP DOCUMENT tm2424255-4_4aseq1.xml 4/A 4787
  Complete submission text file 0001104659-24-100745.txt   6262
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Issuer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK REHOVOT L3 7670402
Business Address
Wiley Matthew T. (Reporting) CIK: 0001759703 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-38410 | Film No.: 241305819